title: Heart failure: acute ischemic events in HF--should we include sudden death?
authors.affiliation: British Heart Foundation Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow G12 8QQ, UK. john.mcmurray@glasgow.ac.uk
authors.forename: John J V
authors.initials: JJ
authors.lastname: McMurray
mesh_terms: D058671:Adrenergic beta-1 Receptor Antagonists / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001578:Benzopyrans / Q000627:therapeutic use; D016757:Death, Sudden, Cardiac / Q000517:prevention & control*; D018450:Disease Progression; D004983:Ethanolamines / Q000627:therapeutic use; D006333:Heart Failure / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D008790:Metoprolol / Q000627:therapeutic use; D017202:Myocardial Ischemia / Q000473:pathology*; D000068577:Nebivolol; D011379:Prognosis; D011433:Propranolol / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D058671:Adrenergic beta-1 Receptor Antagonists; D000959:Antihypertensive Agents; D001578:Benzopyrans; D004983:Ethanolamines; D014665:Vasodilator Agents; D000068577:Nebivolol; D011433:Propranolol; D008790:Metoprolol